Vivos (RDGL) Short term Debt (2011 - 2023)

Vivos' (RDGL) quarterly Short term Debt came in at $10000.0 in Q3 2023, down 68.86% quarter-over-quarter from $32110.0 in Q3 2021.

Analysis

Vivos (RDGL) Short term Debt (2011 - 2023) Analysis & Trends

Vivos has disclosed Short term Debt across 12 years of filings, most recently posting $10000.0 for Q3 2023.

In Q3 2023, Short term Debt changed N/A year-over-year to $10000.0; the TTM figure through Sep 2023 stood at $10000.0 (changed N/A YoY), while the FY2020 annual figure was $32110.0, changed 0.0% from the prior year.
Short term Debt came in at $10000.0 for Q3 2023 at Vivos, down from $32110.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $42110.0 in Q1 2019 to a low of $10000.0 in Q3 2023.
Average Short term Debt over 4 years is $30931.2, with a median of $32110.0 recorded in 2019.
Year-over-year, Short term Debt tumbled 64.38% in 2020 and jumped 114.07% in 2021.
Over 4 years, Short term Debt stood at $32110.0 in 2019, then changed by 0.0% to $32110.0 in 2020, then changed by 0.0% to $32110.0 in 2021, then plunged by 68.86% to $10000.0 in 2023.
Per Business Quant data, the three most recent Short term Debt figures were $10000.0 in Q3 2023, $32110.0 in Q3 2021, and $32110.0 in Q2 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.04 Bn	177.44 Bn	7.27 Bn
2	Intuitive Surgical	125.02 Bn	119.81 Bn	1.96 Bn
3	Medtronic	117.84 Bn	109.02 Bn	6.34 Bn
4	Stryker	105.50 Bn	102.02 Bn	4.50 Bn
5	Boston Scientific	66.27 Bn	65.73 Bn	3.85 Bn
6	Edwards Lifesciences	49.60 Bn	45.35 Bn	1.35 Bn
7	Alcon	33.70 Bn	32.24 Bn	1.68 Bn
8	Dexcom	32.06 Bn	30.11 Bn	830.00 Mn
9	Steris	21.02 Bn	20.54 Bn	684.20 Mn
10	Vivos	23.21 Mn	23.21 Mn	-

Historic Data

Download Data